IL-18 Peptides and Proteins

BT-018-AFL) grades of Recombinant Human IL-18/IL-1F4 as measured by its ability to induce IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells in the presence of TNF-alpha (orange and green, respectively)." class="big_lightbox"> BT-018-AFL) grades of Recombinant Human IL-18/IL-1F4 as measured by its ability to induce IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells in the presence of TNF-alpha (orange and green, respectively)." class="big_thumb" />

CCM037) supplemented with IL-2 (Catalog # BT-002-GMP), IL-12 (Catalog # 10018-IL), IL-15 (Catalog # BT-015-GMP), IL-18 (Catalog # BT-018-GMP), and IL-21 (Catalog # BT-021-GMP) on plates coated with anti-human NKp46 (Catalog # MAB1850). PBMCs were plated to contain 1.8e4 NK cells as determined by flow cytometry on day 0. On day 5, 0.1e6 total cells were taken to seed a 6 well plate. Viability, expansion, and NK purity were analyzed on day 9, with n=5 +/- SEM. A: Total expansion of CD56+ CD3- cells between day 0 and day 9. B: PBMCs grown in ExCellerate NK Cell Expansion Media supplemented with cytokines exhibit viability greater than 80% at day 9." class="big_lightbox"> CCM037) supplemented with IL-2 (Catalog # BT-002-GMP), IL-12 (Catalog # 10018-IL), IL-15 (Catalog # BT-015-GMP), IL-18 (Catalog # BT-018-GMP), and IL-21 (Catalog # BT-021-GMP) on plates coated with anti-human NKp46 (Catalog # MAB1850). PBMCs were plated to contain 1.8e4 NK cells as determined by flow cytometry on day 0. On day 5, 0.1e6 total cells were taken to seed a 6 well plate. Viability, expansion, and NK purity were analyzed on day 9, with n=5 +/- SEM. A: Total expansion of CD56+ CD3- cells between day 0 and day 9. B: PBMCs grown in ExCellerate NK Cell Expansion Media supplemented with cytokines exhibit viability greater than 80% at day 9." class="big_thumb" />

CCM037) supplemented with IL-2 (Catalog # BT-002-GMP), IL-12 (Catalog # 10018-IL), IL-15 (Catalog # BT-015-GMP), IL-18 (Catalog # BT-018-GMP), and IL-21 (Catalog # BT-021-GMP) on plates coated with anti-human NKp46 (Catalog # MAB1850). PBMCs were plated to contain 1.8e4 NK cells as determined by flow cytometry on day 0. On day 5, 0.1e6 total cells were taken to seed a 6 well plate. Viability, expansion, and NK purity were analyzed on day 9, with n=5 +/- SEM for day 9; n=1 for day 0. A: Purity of NK cells at day 9. B: NK ExCellerate media preferentially expands CD56+ NK cells. Percentage of CD56+ cells in culture rose from less than 10% in both donors to more than 60% by day 9. " class="big_lightbox"> CCM037) supplemented with IL-2 (Catalog # BT-002-GMP), IL-12 (Catalog # 10018-IL), IL-15 (Catalog # BT-015-GMP), IL-18 (Catalog # BT-018-GMP), and IL-21 (Catalog # BT-021-GMP) on plates coated with anti-human NKp46 (Catalog # MAB1850). PBMCs were plated to contain 1.8e4 NK cells as determined by flow cytometry on day 0. On day 5, 0.1e6 total cells were taken to seed a 6 well plate. Viability, expansion, and NK purity were analyzed on day 9, with n=5 +/- SEM for day 9; n=1 for day 0. A: Purity of NK cells at day 9. B: NK ExCellerate media preferentially expands CD56+ NK cells. Percentage of CD56+ cells in culture rose from less than 10% in both donors to more than 60% by day 9. " class="big_thumb" />

BT-018-GMP) Animal-Free (Catalog # BT-018-AFL) and RUO (BT-018) grades of Recombinant Human IL‑18/IL‑1F4 as measured in a IFN-gamma secretion assay using KG‑1 human acute myelogenous leukemia cells (orange, green, red, respectively)." class="big_lightbox"> BT-018-GMP) Animal-Free (Catalog # BT-018-AFL) and RUO (BT-018) grades of Recombinant Human IL‑18/IL‑1F4 as measured in a IFN-gamma secretion assay using KG‑1 human acute myelogenous leukemia cells (orange, green, red, respectively)." alt="Equivalent bioactivity of GMP (BT-018-GMP) Animal-Free (Catalog # BT-018-AFL) and RUO (BT-018) grades of Recombinant Human IL‑18/IL‑1F4 as measured in a IFN-gamma secretion assay using KG‑1 human acute myelogenous leukemia cells (orange, green, red, respectively)." class="big_thumb" />

11236-BP) is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human IL-18/IL-1F4 (Catalog # BT9124) that produces 50% of the binding response is 1.50-12.0 ng/mL." class="big_lightbox"> 11236-BP) is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human IL-18/IL-1F4 (Catalog # BT9124) that produces 50% of the binding response is 1.50-12.0 ng/mL." alt="Measured by its binding ability in a functional ELISA. When Recombinant Human IL-18 BPa His-tag Protein (11236-BP) is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human IL-18/IL-1F4 (Catalog # BT9124) that produces 50% of the binding response is 1.50-12.0 ng/mL." class="big_thumb" />